{"disease":{"id":"influenza-immunization","name":"influenza immunization"},"drugs":{"marketed":[{"drug_id":"licensed-influenza-vaccine-3","indication_name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed Influenza Vaccine 3","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Influenza virus hemagglutinin protein","drug_class":"Vaccine","quality_score":37,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04038333","title":"Financing Strategies of Influenza Vaccination in China","phase":"","overall_status":"COMPLETED","enrollment_count":13542,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06800885","title":"Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT04498832","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2100,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06059456","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","phase":"","overall_status":"COMPLETED","enrollment_count":2078,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06413121","title":"Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1557,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT04024228","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1539,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT05513053","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1308,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06765187","title":"A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire","phase":"","overall_status":"COMPLETED","enrollment_count":1007,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06695130","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":980,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06695117","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":980,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06361875","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":910,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06907511","title":"Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":720,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05650554","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":682,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05624606","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":682,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT07282795","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05553301","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06118151","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05513391","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":366,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT04969276","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06727058","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":276,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05426174","title":"Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05829356","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05050318","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT04551677","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}